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EDITORIAL COMMENT
Smoking Cessation in Heart
Failure: It Is Never Too Late*
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Kirsten E. Fleischmann, MD, MPH, FACC,
Stanton A. Glantz, PHD, FACC
San Francisco, California
Smoking control efforts have focused recently on primary
prevention among teens, rather than adult cessation. This
preoccupation with youth has reinforced the feeling that
current smokers are a “lost cause.” There is also a feeling
that once smoking has led to clinical disease, it is too late to
intervene in a way that will help the patient. The article by
Suskin et al. (1) in this issue of the Journal dispels these
myths and illustrates that smoking cessation among smokers
with heart failure is as effective or more effective at reducing
mortality as treatment with beta-blockers or angiotensin-
converting enzyme (ACE) inhibitors. Ex-smokers had a
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30% lower mortality compared to current smokers, which
was similar to that in never smokers. The benefits of smoking
cessation were comparable to treatment with the ACE inhib-
itor enalapril (19% mortality reduction compared to placebo
[2]), the beta-blocker metoprolol (34% mortality reduction [3])
or the aldosterone inhibitor spironolactone (30% mortality
reduction [4]). The benefits of smoking cessation accrue
rapidly in these patients with heart failure, within one year.
Rather than being preventive care, as many physicians
and policy makers consider smoking cessation, the work of
Suskin et al. (1) reinforces the message that smoking
cessation is really therapy.
Despite this clear clinical benefit to patients, most phy-
sicians still do not intervene to treat their patients’ tobacco
use. Population-based surveys indicate that among smokers
who had seen a physician within the last year, less than half
(46%) were advised to quit, and only 15% reported being
offered cessation therapy (5). Similarly, while a majority of
primary care physicians surveyed indicated they ask about
smoking status and advise patients to quit, few reported
actively assisting patients (35%) or arranged follow-up (8%)
as guidelines recommend (6). Physician compliance with
smoking cessation advice among those treating people with
heart failure is equally low; in a retrospective review of 522
congestive heart failure patients admitted at seven university
hospitals, 72% of “ideal” candidates received ACE inhibi-
tors on discharge but only 9% of smokers had documented
advice to quit smoking (7). While the actual level of advice
may be higher than is documented in the medical record, it
is clearly low.
The findings of Suskin et al. (1) have important impli-
cations for both clinical practice and health-care policy. In
clinical practice, it is important to determine the smoking
status of patients with heart failure, promote smoking
cessation and monitor compliance. Some physicians may
believe that smoking cessation counseling is not worth the
effort because of poor patient compliance stemming from
nicotine addiction. In fact, the evidence indicates that
compliance with a well designed smoking cessation coun-
seling program is comparable to that of ACE inhibitors for
patients with serious cardiovascular disease. A randomized
controlled trial of smoking cessation counseling with
monthly telephone follow-up for patients with myocardial
infarction produced six-month and one-year patient com-
pliance rates of 67% and 55% (8), respectively. Minimal
cessation advice, consisting of viewing a smoking cessation
video, a 10-min counseling session and referral to smoking
cessation programs, resulted in six-month and one-year
cessation rates of 43% and 34% (8), respectively. Studies of
compliance with ACE inhibitors have found six-month
compliance rates of from 46% to 86% in patients with heart
failure (9,10).
Given the expense of commonly used medications for
heart failure, smoking cessation counseling with follow-up
may be more cost effective than pharmaceutical treatment
for heart failure to achieve comparable results in terms of
mortality. (Of course, one would expect better results from
the combined effects of smoking cessation and other treat-
ments.) The expected cost of creating a permanent ex-
smoker has been estimated to range from $400 (physician
counseling) to $1,100 (a four to eight week course of
nicotine transdermal patch therapy) (11). The annual cost of
ACE inhibitors and beta-blockers ranges from $200 to
$1,500 per year (12–14). The relative cost of smoking
cessation therapy is lower than appears from this compari-
son because the cost of smoking cessation is a one-time
investment, while the cost of pharmaceutical therapy con-
tinues for the life of the patient. In addition, at an average
cost of $4.50 per pack, an ex-pack-a-day smoker would save
$1,600 a year on cigarettes.
The policy issue is coverage of smoking cessation therapy
by health insurance programs. Physicians often complain
that smoking cessation therapy is not reimbursed as a
separate service. While it would provide a financial incentive
to provide this service if it were separately reimbursable, the
fact remains that prescribing and supervising the use of
beta-blockers and ACE inhibitors is not a separately reim-
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bursed service. Proper prescription and monitoring of these
drugs is simply good medical practice and the standard of
care for patients with severe cardiovascular disease. There is
no reason that proper prescription and monitoring of
smoking cessation efforts should not be treated similarly.
It is, however, possible to obtain additional compensation
for smoking cessation efforts. Smoking cessation therapy is
considered preventive care for tobacco dependence recorded
as a primary disease, and is therefore often not covered by
fee-for-service insurance policies and is not covered at all by
Medicare. However, when tobacco dependence can be
documented as a contributing factor to a smoking-related
disease, such as heart failure, smoking cessation therapy is
often covered. With proper documentation, Medicare will
consider coverage on a case-by-case basis. Individual state
Medicaid programs and private insurance company policies
vary widely. Proper documentation of tobacco dependence
as a contributing factor to a primary smoking-related disease
is important for justifying coverage.
Health care advocates should also work to make tobacco
cessation therapy more widely and easily available for
patients with cardiovascular disease, in both fee-for-service
and managed care settings. Insurance coverage should be as
easily available for smoking cessation therapy as for drug
therapy. Drug therapy is widely accepted and the required
mechanisms for prescribing and dispensing are in place. The
article by Suskin et al. (1) provides compelling evidence that
smoking cessation should simply be considered one more
clinical intervention in these patients. Unlike the use of
powerful drugs, the side effects of smoking cessation—
reducing the risks of other diseases—are positive.
When medical professionals and the general public think
about smoking, they generally think of cancer, even though
heart disease is a major disease end point for tobacco use.
Moreover, unlike cancer, the benefits of smoking cessation
in terms of reducing risk of cardiovascular disease accrue
rapidly. (Other benefits, such as reductions in cancer risk,
also accrue, albeit more slowly.) In otherwise healthy indi-
viduals, the risk of a heart attack or stroke falls by half
within the first year following cessation and is nearly back to
that of a nonsmoker in three years (15). Indeed, in Califor-
nia, the short-term savings in direct medical costs associated
with these heart attacks and strokes alone amounted to
enough money (15) to pay for a major public tobacco
control program that has been in place since 1989 (16).
Because of the rapid impact on heart disease risk, the
California program prevented 33,300 coronary heart disease
deaths during its first 7 years (17). These rapid public health
benefits in tobacco prevention and cessation do not come
from primary prevention of smoking in children, they come
from reducing adult smoking rates and the attendant reduc-
tions in heart disease.
Suskin et al. (1) show that even in patients with estab-
lished and serious cardiovascular disease, smoking cessation
is an effective measure for the prevention of death and
hospitalization. Quitting smoking is as effective as modern
pharmaceutical therapies, and just as fast in manifesting its
benefits. It is never too late to quit smoking, even for patients
with heart failure and other serious cardiovascular disease.
Cardiologists need to incorporate aggressive efforts to promote
smoking cessation into practice in the same way that they have
incorporated ACE inhibitors and beta-blockers.
To do anything less would be to deny these patients the
best care.
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